« Back to Record
Cameron, D. A., Gianni, L., Baselga, J., Al-Sakaff, N., Lauer, S., McFadden, E., Leyland-Jones, B., Bell, R. H., Dowsett, M., Jackisch, C., Piccart-Gebhart, M., Gelber, R., Procter, M., Goldhirsch, A., de Azambuja, E., Castro, G., Untch, M., & Smith, I. I. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet, 389(10075), 1195-1205. doi:10.1016/S0140-6736(16)32616-2
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/249631



